Strs Ohio Has $2.20 Million Stock Position in Exelixis, Inc. $EXEL

Strs Ohio lifted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 712.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51,303 shares of the biotechnology company’s stock after acquiring an additional 44,991 shares during the period. Strs Ohio’s holdings in Exelixis were worth $2,200,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in EXEL. Dimensional Fund Advisors LP lifted its holdings in shares of Exelixis by 11.2% in the third quarter. Dimensional Fund Advisors LP now owns 4,180,912 shares of the biotechnology company’s stock valued at $172,658,000 after purchasing an additional 419,596 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Exelixis by 62.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 187,154 shares of the biotechnology company’s stock valued at $8,224,000 after buying an additional 71,987 shares during the last quarter. Stephens Investment Management Group LLC raised its position in Exelixis by 1.1% in the 4th quarter. Stephens Investment Management Group LLC now owns 2,539,421 shares of the biotechnology company’s stock valued at $111,303,000 after buying an additional 28,265 shares during the last quarter. Private Client Services LLC purchased a new position in Exelixis during the 4th quarter worth $1,992,000. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Exelixis by 692.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 140,446 shares of the biotechnology company’s stock valued at $6,156,000 after purchasing an additional 122,720 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insider Activity

In other news, Director George Poste sold 60,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $45.71, for a total transaction of $2,742,600.00. Following the completion of the sale, the director owned 118,832 shares in the company, valued at $5,431,810.72. This trade represents a 33.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Christopher J. Senner sold 34,901 shares of Exelixis stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $50.00, for a total transaction of $1,745,050.00. Following the completion of the sale, the chief financial officer directly owned 952,317 shares in the company, valued at $47,615,850. This trade represents a 3.54% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 219,170 shares of company stock worth $10,620,641. 2.60% of the stock is owned by insiders.

Exelixis Trading Up 1.7%

Shares of NASDAQ:EXEL traded up $0.92 during midday trading on Tuesday, reaching $56.45. The company had a trading volume of 338,809 shares, compared to its average volume of 2,717,560. The company’s 50 day moving average price is $50.75 and its 200 day moving average price is $46.10. The stock has a market cap of $14.19 billion, a P/E ratio of 18.66, a P/E/G ratio of 1.61 and a beta of 0.42. Exelixis, Inc. has a 52-week low of $33.76 and a 52-week high of $56.88.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.12. The company had revenue of $610.81 million during the quarter, compared to analyst estimates of $607.51 million. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.55 earnings per share. Research analysts forecast that Exelixis, Inc. will post 3.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

EXEL has been the topic of a number of recent analyst reports. Barclays raised their price target on shares of Exelixis from $44.00 to $45.00 and gave the company an “equal weight” rating in a research report on Monday, April 20th. Morgan Stanley reiterated a “positive” rating on shares of Exelixis in a research note on Monday, June 22nd. Royal Bank Of Canada reissued a “sector perform” rating and set a $46.00 target price on shares of Exelixis in a research report on Tuesday. Stifel Nicolaus boosted their target price on Exelixis from $44.00 to $47.00 and gave the stock a “hold” rating in a research note on Wednesday, May 6th. Finally, Truist Financial upped their target price on Exelixis from $54.00 to $56.00 and gave the company a “hold” rating in a report on Tuesday. Nine research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $47.93.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.